We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Researchers Use NIV Methods for Diagnosis of Endometrial Cancer

By LabMedica International staff writers
Posted on 01 Jul 2019
A team of Catalan cancer researchers has suggested using materials containing biomarkers and cellular debris collected during routine Pap smears and other non-invasive sampling methods as the basis for genomic diagnosis of endometrial cancer.

Currently, methods for detecting endometrial cancer are limited to high-risk populations and symptomatic women, since 90% of endometrial cancers present with abnormal bleeding. More...
To improve this situation, investigators at Bellvitge Biomedical Research Institute (Barcelona, Spain) and collaborators in Catalonia and abroad suggested taking advantage of the anatomical continuity of the uterine cavity with the cervix. By doing so, they suggested the possibility of genomic exploitation of material from routine, non-invasive sampling methods. This would represent a unique opportunity to detect signs of disease using biological material shed from the upper genital tract.

The investigators have taken initial steps in this process by recruiting nearly 500 female subjects and gathering more than 1,600 biological samples for analysis.

Certain questions remain to be addressed in order to accelerate the implementation of novel technologies for routine screening in a clinical setting. In this regard, the investigators discussed new perspectives on detection of endometrial cancer using genomic and other biomarkers in minimally invasive sampling methods in a paper published in the June 19, 2019, online edition of the International Journal of Cancer.

Related Links:
Bellvitge Biomedical Research Institute


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.